Venner Shipley’s world leading inflammasome client, Inflazome, acquired by Roche
We are pleased to announce that our client Inflazome has been acquired by the global pharmaceutical company Roche in a deal in which Inflazome’s shareholders received an upfront payment of €380 million and are eligible to receive additional undisclosed milestone payments in the future.
Inflazome is a pioneering biotech company leading the development of small molecule pharmaceuticals to address clinical unmet needs in inflammatory diseases by targeting the NLRP3 inflammasome which is understood to drive many chronic inflammatory conditions, from Parkinson’s and Alzheimer’s to asthma, inflammatory bowel disease, chronic kidney disease, cardiovascular disease, arthritis and NASH.
Venner Shipley Partners, Dr Allie Elend and Dr Stephen Johnson have acted for Inflazome from its inception in 2016 and have been instrumental in developing Inflazome’s intellectual property portfolio, laying the foundation to attract such a significant investment.
Dr David Miller, Director of Medicinal Chemistry at Inflazome comments, “Your [Venner Shipley’s] partnership with us has helped to get Inflazome to this landmark and we want to thank you all for the contributions you have made to this success”.
This deal highlights the importance of securing comprehensive intellectual property to capture the true value of your business, for which Venner Shipley has a proven track record.
For further information on the acquisition, please click here.
